Cite
APA Citation
Chow, S., Evans, M., Galvis, V., Leach, R., Keene, E., Chan, K., Spencer-Shaw, A., Jonathan, S., Shabalak, A., Thistlethwaite, F., & Hawkins, R. (n.d.). high-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection. Journal for immunotherapy of cancer, 2, . http://access.bl.uk/ark:/81055/vdc_100137793564.0x000006